Literature DB >> 17998511

Visual acuity in 3422 consecutive eyes with choroidal nevus.

Carol L Shields1, Minoru Furuta, Arman Mashayekhi, Edwina L Berman, Jonathan D Zahler, Daniel M Hoberman, Diep H Dinh, Jerry A Shields.   

Abstract

OBJECTIVE: To evaluate visual acuity in eyes with choroidal nevus.
DESIGN: This was an observational case series. Of 3422 consecutive eyes with choroidal nevus, vision loss at 15 years occurred in 2% of eyes with extrafoveolar nevus and in 26% of eyes with subfoveolar nevus, particularly those with overlying retinal pigment epithelial detachment and foveal edema. A retrospective medical record review was conducted, with evaluation of visual acuity at presentation and at final examination. The main outcome measure was visual acuity.
RESULTS: The median visual acuity at presentation was 20/20 for eyes with either extrafoveolar or subfoveolar choroidal nevus. Using Kaplan-Meier estimates, vision loss of 3 or more logarithm of the minimum angle of resolution (logMAR) lines at 5, 10, and 15 years occurred in less than 1%, 1%, and 2% of eyes with extrafoveolar nevus compared with 15%, 20%, and 26% of eyes with subfoveolar choroidal nevus, respectively. By multivariate analysis, factors predictive of visual loss of 3 or more logMAR lines included subfoveolar nevus location (relative risk [RR], 15.52), juxtapapillary nevus location (RR, 4.52), initial visual acuity of 20/50 or worse (RR, 15.40), overlying retinal pigment epithelial detachment (RR, 22.16), and foveal edema (RR, 9.02). Factors predictive of poor final visual acuity of 20/200 or worse included subfoveolar nevus location (RR, 11.32), overlying orange pigment (RR, 3.68), overlying retinal pigment epithelial detachment (RR, 12.80), and foveal edema (RR, 18.72).
CONCLUSION: Mild vision loss over many years should be anticipated in patients with subfoveolar choroidal nevus, particularly those with overlying retinal pigment epithelial detachment, orange pigment, and foveal edema.

Entities:  

Mesh:

Year:  2007        PMID: 17998511     DOI: 10.1001/archopht.125.11.1501

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  8 in total

1.  Optical coherence tomography of retinal and choroidal tumors.

Authors:  Emil Anthony T Say; Sanket U Shah; Sandor Ferenczy; Carol L Shields
Journal:  J Ophthalmol       Date:  2011-07-18       Impact factor: 1.909

Review 2.  Review of spectral domain enhanced depth imaging optical coherence tomography of tumors of the choroid.

Authors:  Carol L Shields; Janet Manalac; Chandana Das; Jarin Saktanasate; Jerry A Shields
Journal:  Indian J Ophthalmol       Date:  2015-02       Impact factor: 1.848

3.  Selective retina therapy for subretinal fluid associated with choroidal nevus.

Authors:  Manabu Yamamoto; Yoko Miura; Akika Kyo; Kumiko Hirayama; Takeya Kohno; Dirk Theisen-Kunde; Ralf Brinkmann; Shigeru Honda
Journal:  Am J Ophthalmol Case Rep       Date:  2020-06-23

4.  Optical coherence tomography of retinal and choroidal tumors.

Authors:  Emil Anthony T Say; Sanket U Shah; Sandor Ferenczy; Carol L Shields
Journal:  J Ophthalmol       Date:  2011-06-08       Impact factor: 1.909

5.  Treatment of vascular activity secondary to atypical choroidal nevus using intravitreal bevacizumab.

Authors:  Milena L Cavalcante; Victor M Villegas; Aaron S Gold; Ludimila L Cavalcante; Marcela Lonngi; Nisha V Shah; Timothy G Murray
Journal:  Clin Ophthalmol       Date:  2014-07-22

6.  Choroidal nevus and polypoidal vasculopathy: case series.

Authors:  Karlos Ítalo S Viana; Pedro F Dalgalarrondo; Zelia Correa; Rodrigo Jorge
Journal:  Int J Retina Vitreous       Date:  2020-06-02

7.  Treatment response to intravitreal bevacizumab in small pigmented choroidal lesions with subretinal fluid.

Authors:  Junwon Lee; Hee Jung Kwon; Min Kim; Christopher Seungkyu Lee; Sung Chul Lee
Journal:  BMC Ophthalmol       Date:  2019-05-03       Impact factor: 2.209

8.  Malignant transformation of choroidal nevus according to race in 3334 consecutive patients.

Authors:  Charlotte L Marous; Carol L Shields; Michael D Yu; Lauren A Dalvin; David Ancona-Lezama; Jerry A Shields
Journal:  Indian J Ophthalmol       Date:  2019-12       Impact factor: 1.848

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.